Login to Your Account



NewCo News

Cytogel Seeks to Impact Pain Management Market

By Marie Powers


Thursday, April 28, 2011
After nearly a decade of effort, biopharmaceutical development company Cytogel Pharma LLC recently moved its lead candidate – a chemically stabilized analogue of endomorphin (EM) 1 designed to treat acute and chronic pain – into the clinic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription